{
    "nctId": "NCT00544804",
    "briefTitle": "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2",
    "officialTitle": "A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Maximum tolerated dose of Lapatinib",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Advanced or metastatic disease\n  * No effective curative therapy available\n* Bone-only disease allowed\n* Tumor HER2 overexpression\n\n  * HER2 3+ expression by immunohistochemistry OR \\> 2-fold (HER2 2+) gene amplification by fluorescence in situ hybridization\n* Evaluable disease\n\n  * Measurable disease is not required\n* No progressive brain metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* Female\n* Menopausal status not specified\n* Absolute neutrophil count \u2265 1,000 cells/mm\\^3\n* Hemoglobin \u2265 9 g/dL\n* Platelet count \u2265 75,000 cells/mm\\^3\n* Total bilirubin normal\n* AST and ALT \u2264 3 x upper limits of normal (ULN) (\u2264 5 x ULN with liver metastases)\n* Creatinine normal OR creatinine clearance \u2265 40 mL/min\n* INR \u2264 1.5\n* Potassium normal\n* Magnesium normal\n* Not pregnant\n* Negative pregnancy test\n* Fertile patients must use effective contraception prior to and during study therapy\n* Cardiac ejection fraction \u2265 50%\n* Consents to 2 tumor fine needle aspiration biopsies for biomarker analysis\n\n  * Lung-only disease or sites otherwise deemed high-risk for biopsy, the requirement for biopsy will be waived\n\nExclusion criteria:\n\n* History of significant cardiac disease including any of the following:\n\n  * Congestive heart failure\n  * Symptomatic cardiac arrhythmias\n  * Unstable angina\n* Uncontrolled prior lapatinib ditosylate therapy toxicity \u2265 grade 2\n* Allergic reactions to IV contrast dye despite standard prophylaxis\n* History of malabsorption syndrome or disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism, or excretion of study drug\n* Conditions that would impair the patient's ability to swallow and retain oral medication\n* Concurrent disease or condition that would make the patient inappropriate for study participation or would interfere with the patient's safety\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior lapatinib ditosylate or trastuzumab allowed\n* At least 4 weeks since prior and no concurrent chemotherapy or investigational anticancer agents\n* At least 2 weeks since prior and no concurrent hormonal therapy\n* At least 2 weeks since prior and no concurrent lapatinib ditosylate prohibited medications, including CYP3A4 inhibitors or inducers, all herbal supplements, and gastric pH modifiers\n* More than 4 weeks since prior radiotherapy\n* No aspirin or plavix therapy within 7 days prior to tumor biopsy\n* No concurrent coumadin\n\n  * Low molecular weight heparin allowed provided it can be held at least 24 hours prior to tumor biopsy\n* Concurrent gonadal suppression agents (i.e., Zoladex or Lupron) or palliative bisphosphonates (i.e., Zometa) allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}